The Russian Foundation for direct investment (RDII) announced the results of a clinical study on the combined use of the Astrazeneca vaccine and the first component of the “satellite V”. The study is carried out in Azerbaijan, reports “Kommersant”.
Research and immunogenicity of the combination of the Astrazeneca vaccine and the first component of the Vaccine “Satellite V” in Azerbaijan began in February 2021, there are 50 volunteers vaccinated, the set in a clinical study continues. Intermediate data analysis demonstrates high safety indicators of combined drugs : There are no serious undesirable phenomena, as well as cases of coronavirus disease after vaccination, “- reported on the website of the RFP.
The first data on immunogenicity of the combined use of drugs of the RDII and partners intend to publish in August. In addition to Azerbaijan, there is a vaccination of volunteers in the United Arab Emirates, regulators allowed research in Russia and Belarus.